How effective is Fruquintinib?

Clinical trial data on fruquintinib (Fruquintinib) shows that the drug has shown certain clinical efficacy in the treatment of digestive system tumors such as advanced colorectal cancer and gastric cancer. The following will introduce the effect of fruquintinib based on clinical experimental data.

1. Therapeutic effects of advanced colorectal cancer:

Fruquintinib has been used in several pivotal clinical trials in the treatment of advanced colorectal cancer. Among them, an important study is the phase III phase FRESCO trial. The trial is a multicenter, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of fruquintinib in patients with advanced colorectal cancer.

The results of the study showed that patients treated with fruquintinib were significantly better than the placebo group in terms of overall survival (OS) and progression-free survival (PFS). Patients in the fruquintinib group showed a significant increase in overall survival and a significant improvement in progression-free survival compared with placebo. In addition, patients in the fruquintinib group also showed certain positive trends in improving quality of life.

2. Therapeutic effect of gastric cancer:

Fruquintinib’s efficacy in treating gastric cancer has also been supported by some studies. Fruquintinib was studied in patients with advanced gastric cancer in the phase II/III FRESCO-2 trial. The primary endpoints of the study include overall survival, progression-free survival, clinical response rate, etc.

Although specific data may vary based on study design and patient characteristics, preliminary results suggest that fruquintinib provides some improvement in overall survival and progression-free survival compared with placebo. In addition, fruquintinib has shown inhibitory effects on tumors in some patients and is expected to become a potential treatment option for gastric cancer.

3. Safety and Tolerability:

In addition to efficacy, it is critical to understand the safety and tolerability of fruquintinib. According to the results of clinical trials, fruquintinib has a relatively good safety profile. The main adverse reactions include hypertension, hand-foot syndrome, proteinuria, etc. Generally speaking, most of these reactions are controllable and reversible.

It should be pointed out that clinical trial data are still accumulating, and the efficacy and safety of drugs may be affected by many factors such as patient groups and study design. Therefore, when patients consider using fruquintinib, they should do so under the guidance of a professional doctor, who will develop an individualized treatment plan based on the patient's specific situation.

Taken together, fruquintinib, as a targeted therapy, has shown certain efficacy in the treatment of advanced colorectal cancer and gastric cancer. However, the specific treatment effect still needs to be evaluated based on the individual differences and specific conditions of the patient. Patients need to pay close attention to the doctor's advice and treatment effect during use. In the future, as more research is conducted, the understanding and application of fruquintinib may be further deepened.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.